| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 06 Oct 2026 |
Form 4: Bishop Hans Edgar, Director
Received 8,680 shares as a grant or award |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contai... |
| 27 Aug 2026 |
Form 4: Patel Dhavalkumar Dhirajlal, EVP, Chief Scientific Officer
Received 125,000 shares by exercise or conversion · Gave up 41,158 shares to cover exercise price or tax ($169K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness |
| 07 Jul 2026 |
Form 4: Bishop Hans Edgar, Director
Received 6,297 shares as a grant or award |
| 05 Jun 2026 |
Form 4: Yang Patrick Y, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Rosiello Robert L., Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Seitz Michelle, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Reicin Alise, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Mulligan Richard, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Bishop Hans Edgar, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Bilenker Joshua H., Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
Form 4: Nelsen Robert, Director
Granted 90,000 Stock Option (Right to Buy) |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Sana Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on June 4, 2026. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Mee... |
| 21 May 2026 | SCHEDULE 13G |
Loading...